ArticleHeliyon2019
Combination therapy with transcranial magnetic stimulation and ketamine for treatment-resistant depression: A long-term retrospective review of clinical use.
Article in Heliyon, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression.Advances in therapy · 2021Pooled it
- Physical Therapy for Treatment-Resistant Depression A Comprehensive Review of Efficacy, Safety, and Evidence Grading.Neuropsychiatric disease and treatment · 2026Review
- Case Report: Intranasal esketamine and accelerated intermittent theta-burst stimulation for severe treatment-resistant depression with suicidal ideation.Frontiers in psychiatry · 2026Article
- Four dimensions of individualization in brain stimulation for psychiatric disorders: context, target, dose, and timing.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Review
- Therapeutic Approaches to Tackle the Challenge of Depression That Is Resistant to Treatment-A Narrative Review.Health science reports · 2025Article
- Intermittent theta-burst stimulation alleviates hypoxia-ischemia-caused myelin damage and neurologic disability.Experimental neurology · 2024Article
- The Advantages of Combining Therapies in Treating Psychiatric Patients.Brain sciences · 2024Article
- Synergistic use of deep TMS therapy with IV ketamine infusions for major depressive disorder: a pilot study.Psychopharmacology · 2024Article
- Combination of Transcranial Magnetic Stimulation and Ketamine in Treatment-Resistant Depression: A Systematic Review.Cureus · 2024Review
- Multi-objective optimization method for coil current waveform of transcranial magnetic stimulation.Heliyon · 2023Article
- Transcranial magnetic stimulation and ketamine: implications for combined treatment in depression.Frontiers in neuroscience · 2023Review
- Assessing the mechanisms of brain plasticity by transcranial magnetic stimulation.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Review
- TMS-evoked potential in the dorsolateral prefrontal cortex to assess the severity of depression disease: a TMS-EEG study.Frontiers in pharmacology · 2023Article
- Therapeutic Neuromodulation toward a Critical State May Serve as a General Treatment Strategy.Biomedicines · 2022Article
- Transcranial magnetic stimulation and intravenous ketamine combination therapy for treatment-resistant bipolar depression: A case report.Frontiers in psychiatry · 2022Article
- A Retrospective Naturalistic Study Comparing the Efficacy of Ketamine and Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression.Frontiers in psychiatry · 2021Article
- Brain SPECT as an Imaging Biomarker for Evaluating Effects of Novel Treatments in Psychiatry-A Case Series.Frontiers in psychiatry · 2021Article
- Tinnitus and Brain Stimulation.Current topics in behavioral neurosciences · 2021Article
- Repetitive Transcranial Magnetic Stimulation for Adolescent Major Depressive Disorder: A Focus on Neurodevelopment.Frontiers in psychiatry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBoth transcranial magnetic stimulation (TMS) and infused ketamine are recognized treatments for patients suffering from major depressive disorder (MDD). A novel therapy named combination TMS with ketamine (CTK) is introduced. This retrospective review examined the safety and clinical benefits of CTK in patients suffering from treatment-resistant depression (TRD) during the routine practice of psychiatry in a private clinic.
methodsTRD patients (N = 28) received a coincident application of high-output TMS (30 minutes) with biomarker-determined ketamine infusions (20 minutes). Frequency of treatment was dependent on patient responsiveness (10-30 sessions). Clinical global impression (CGI) data was collected pre- and post-treatment and then two years later.
resultsThe mean reduction in CGI severity for the patient group following CTK was 4.46 ± 0.54 at a 99% confidence interval and was deemed statistically significant using a paired t-test (α = 0.01, t = 22.81 p < 0.0001). This reduction was sustained for two years following treatment completion and this remission was deemed statistically significant by a second paired t-test (α = 0.01, t = 27.36, p < 0.0001). LIMITATIONS: Retrospective review of a limited number of patients undergoing CTK in a clinical practice.
conclusionsThis clinical review indicated that CTK is an effective, long-term therapy (after two years) and can be used for TRD patients. The coincident administration of ketamine allowed for higher TMS intensities than otherwise would be tolerated by patients. Further studies for optimization of CTK are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.